These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 33450096)
1. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096 [TBL] [Abstract][Full Text] [Related]
2. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Khanna R; Preiss JC; MacDonald JK; Timmer A Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580 [TBL] [Abstract][Full Text] [Related]
3. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765 [TBL] [Abstract][Full Text] [Related]
4. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease. Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients. Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990 [TBL] [Abstract][Full Text] [Related]
6. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE). Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512 [No Abstract] [Full Text] [Related]
7. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609 [TBL] [Abstract][Full Text] [Related]
8. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study. Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301 [TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease. Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059 [TBL] [Abstract][Full Text] [Related]
10. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627 [TBL] [Abstract][Full Text] [Related]
11. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease]. Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575 [No Abstract] [Full Text] [Related]
12. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials. Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis. Kawalec P; Moćko P; Malinowska-Lipien I; Brzostek T J Comp Eff Res; 2017 Oct; 6(7):601-612. PubMed ID: 28660802 [TBL] [Abstract][Full Text] [Related]
14. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824 [TBL] [Abstract][Full Text] [Related]
15. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry. Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648 [TBL] [Abstract][Full Text] [Related]
16. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction. Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118 [TBL] [Abstract][Full Text] [Related]
17. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease]. Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241 [TBL] [Abstract][Full Text] [Related]
18. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389 [TBL] [Abstract][Full Text] [Related]
19. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice. Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654 [TBL] [Abstract][Full Text] [Related]
20. Aminosalicylates for induction of remission or response in Crohn's disease. Lim WC; Wang Y; MacDonald JK; Hanauer S Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]